Pradžia › Kraujos vėžys › Koloradas
Kraujos vėžys klinikiniai tyrimai Koloradas
14 tyrimai dėl Kraujos vėžys ieško dalyvių vietose Koloradas.
Miestai Koloradas
Oficialus tyrimo tekstas (anglų kalba)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- University of Colorado Cancer Center ( Site 0021), Aurora
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- ir dar 15
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Colorado Blood Cancer Institute ( Site 2726), Denver
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT04728893Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Grand Valley Oncology, Grand Junction
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-17 · NCT04242095Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-10 · NCT06823167A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's Hospital Colorado, Aurora
- University of Colorado Hospital, Aurora
- Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-06 · NCT01351545Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- Childrens Hospital of Colorado, Aurora
Renkami dalyviaiStebimasis tyrimas
Iki 30 metų · Visoms lytims · Atnaujinta 2026-06-18 · NCT06579469A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- Children's Hospital Colorado, Aurora
Renkami dalyviai3 fazė
Amžius nuo 2 iki 18 · Visoms lytims · Atnaujinta 2026-05-05 · NCT05711667A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT05735184Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Colorado, Denver
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.